ICML 2025 | Cellular therapy session at ICML 2025: novel CAR-T approaches for LBCL

So this year at ICML 2025, we’re here live. There have been very exciting abstracts regarding novel cellular therapy approaches for patients with relapsed/refractory large B-cell lymphoma. So yesterday, as a matter of fact, we had a very exciting session on novel cellular therapy approaches. Many of the abstracts focused on CAR-T constructs, which targeted both CD19 and CD20. So different structures of dual-targeted approaches in this relapse/refractory setting. Some included second-line and third-line plus patients. Others focused in the third-line plus setting. Some phase one data, phase two clinical trials. Very exciting. Some products were fresh in, fresh out. So there were no cryopreserved products coming back to the sites, and this allowed for a more rapid infusion of the products. There were also some really quick manufacturing systems with some of the companies. So we’re looking at rapid manufacturing, dual-targeted CAR T-cell products, efficacy, looking great, CR rates over 80, 90% in some of the abstracts. Important to be cautious because there were low numbers in some of those early presentations, but I think it’s still very exciting to be able to offer this novel generation of CAR T-cell constructs to our patients with relapsed/refractory large B-cell lymphoma. When we are looking at this data, it’s also important to interpret if these are CAR-T naive patients or patients who have been previously exposed to autologous CD19 CAR T-cell targeting products. But in any case, looking good, the treatment landscape is definitely exciting. And we look forward to seeing more data regarding these products in the near future, in the near coming meetings.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.